10-QPeriod: Q2 FY2013

Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2013

Filed August 7, 2013For Securities:MRK

Summary

Merck & Co., Inc. reported a significant decrease in sales and net income for the second quarter and first six months of 2013 compared to the prior year. This downturn was primarily driven by the loss of market exclusivity for key products, most notably Singulair, following patent expiries in the U.S. and major European markets. The company also faced challenges from ongoing healthcare cost containment measures and unfavorable foreign exchange rates. Despite the top-line decline, Merck continued to invest in its research and development pipeline, with notable progress in allergy immunotherapy and oncology. The company also initiated substantial share repurchase programs, financed partly by new debt issuance, signaling a focus on returning capital to shareholders. Investors should closely monitor the impact of patent expirations on key products, the performance of newer drugs and vaccines, and the company's ongoing restructuring efforts to improve efficiency.

Financial Highlights

50 data points
Beta

Revenue

$11.01B

61.1% Gross Margin

Net Income

$906.00M

8.2% Net Margin

EPS (Diluted)

$0.30

Total Assets

$106.88B

Cash & Equivalents

$15.09B

Free Cash Flow

$2.34B

Financial Statements
Beta
Revenue$11.01B
Cost of Revenue$4.28B
Gross Profit$6.73B
R&D Expenses$2.10B
SG&A Expenses$3.14B
Interest Expense$201.00M
Net Income$906.00M
EPS (Basic)$0.30
EPS (Diluted)$0.30
Shares Outstanding (Basic)2.98B
Shares Outstanding (Diluted)3.01B

Key Highlights

  • 1Total sales decreased by 11% in Q2 2013 and 10% for the first six months of 2013 compared to the prior year, largely due to the loss of Singulair exclusivity.
  • 2Net income attributable to Merck & Co., Inc. fell significantly, with Q2 2013 net income at $906 million ($0.30 EPS) versus $1,793 million ($0.59 EPS) in Q2 2012.
  • 3The company recorded substantial restructuring costs totaling $278 million in Q2 2013 and $472 million for the first six months of 2013, primarily related to the post-merger integration.
  • 4Research and development expenses remained relatively stable year-over-year, with a slight decrease in Q2 2013, indicating continued investment in pipeline development.
  • 5Merck announced and initiated significant share repurchase programs, including a $5 billion accelerated share repurchase (ASR), financed by new debt issuance.
  • 6Sales of key growth drivers like Gardasil and Januvia showed mixed performance, with Gardasil sales up 18% in Q2, while Januvia sales saw a 1% decline in Q2.
  • 7The company recognized significant intangible asset impairment charges, including $330 million for Saphris/Sycrest and $181 million for preladenant due to clinical development discontinuation.

Frequently Asked Questions

The primary reason for the decline in sales and net income is the loss of market exclusivity for key products, most notably Singulair, following patent expiries in the U.S. (August 2012) and major European markets (February 2013). This led to a significant and rapid drop in sales for these products.

Merck is actively engaged in restructuring programs, primarily the Merger Restructuring Program initiated after the Schering-Plough merger, designed to optimize cost structure. These programs involve workforce reductions and facility rationalizations. The company incurred substantial restructuring costs related to these efforts and expects them to be substantially completed by the end of 2013, with some manufacturing-related actions extending to 2016.

Merck has a strong focus on returning capital to shareholders. This is evidenced by its announcement of a new share repurchase program authorizing up to $15 billion in stock purchases and the execution of a $5 billion accelerated share repurchase (ASR) agreement. These repurchases are being financed through a combination of operating cash flows and new debt issuance.

Merck is involved in various legal proceedings, including significant litigation related to Vioxx and Fosamax. The company has established reserves for some settlements (e.g., Vioxx Canadian settlement, Missouri Vioxx consumer claims) and is actively defending against other claims. While the company believes it has meritorious defenses, unfavorable outcomes in these matters could have a material adverse effect on its financial position, liquidity, and results of operations.